Royal Bank of Canada Buys 10,895 Shares of Natera, Inc. $NTRA

Royal Bank of Canada grew its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 6.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 171,336 shares of the medical research company's stock after buying an additional 10,895 shares during the period. Royal Bank of Canada owned 0.13% of Natera worth $24,229,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. HighPoint Advisor Group LLC raised its position in Natera by 30.8% during the 1st quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company's stock worth $308,000 after buying an additional 468 shares during the last quarter. Amalgamated Bank grew its holdings in shares of Natera by 9.8% during the first quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock worth $1,173,000 after buying an additional 740 shares in the last quarter. GAMMA Investing LLC grew its holdings in Natera by 32.3% in the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock valued at $120,000 after purchasing an additional 207 shares during the period. Comerica Bank raised its holdings in shares of Natera by 24.1% during the 1st quarter. Comerica Bank now owns 141,106 shares of the medical research company's stock valued at $19,954,000 after buying an additional 27,379 shares during the period. Finally, Teza Capital Management LLC purchased a new stake in shares of Natera during the 4th quarter valued at about $221,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Price Performance

NASDAQ:NTRA traded down $4.06 during mid-day trading on Friday, reaching $169.75. The stock had a trading volume of 437,496 shares, compared to its average volume of 1,466,838. The stock has a 50-day simple moving average of $155.04 and a two-hundred day simple moving average of $154.09. The stock has a market capitalization of $23.30 billion, a PE ratio of -88.83 and a beta of 1.68. Natera, Inc. has a 12 month low of $117.27 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. During the same period in the prior year, the firm earned ($0.30) EPS. The business's revenue for the quarter was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. Equities analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $166.62, for a total value of $499,860.00. Following the sale, the insider directly owned 120,859 shares in the company, valued at approximately $20,137,526.58. The trade was a 2.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider John Fesko sold 678 shares of Natera stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $155.46, for a total value of $105,401.88. Following the transaction, the insider directly owned 152,747 shares of the company's stock, valued at $23,746,048.62. The trade was a 0.44% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,423 shares of company stock worth $8,459,656. Corporate insiders own 5.63% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Morgan Stanley reiterated an "overweight" rating and issued a $195.00 target price on shares of Natera in a research report on Sunday, August 10th. Evercore ISI upgraded shares of Natera to a "strong-buy" rating and set a $170.00 price objective for the company in a research report on Monday, July 28th. Cowen restated a "buy" rating on shares of Natera in a report on Friday, August 8th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $220.00 target price (up from $210.00) on shares of Natera in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $194.00.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.